中 / EN

BCIwiki — Brain-computer interface news, research and industry database

Latest

November 2025

UNESCO Adopts Neurotech Ethics Standard

UNESCO's 43rd General Conference adopted the Recommendation on the Ethics of Neurotechnology, the first global framework, backed by 194 Member States.
Why it matters Backed by all 194 Member States, this first global neurotech ethics framework elevates mental privacy and neural data protection to worldwide consensus, and will shape national legislation the way UNESCO's AI ethics recommendation shaped AI governance

Synchron Raises $200 Million Series D, Bringing Total Funding to $345 Million

Synchron raised a $200 million Series D led by Double Point Ventures, taking its total funding to $345 million. The company plans to use the capital to commercialize its Stentrode endovascular BCI, prepare pivotal trials and expand its AI and engineering teams. Synchron said 10 people with paralysis had received the implant in U.S. and Australian trials at the time of the announcement.
Why it matters The round sets a clear capital benchmark for moving an implantable BCI from small feasibility studies toward pivotal trials and launch preparation.
October 2025

FDA Clears Persyst 15 EEG Review Software

The FDA cleared Persyst Development's Persyst 15 EEG Review and Analysis Software on October 31, 2025, finding it substantially equivalent under submission number K252160 through the traditional 510(k) pathway. The agency classifies it as Automatic Event Detection Software for Full-Montage Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. The category covers software that automatically flags events within full-montage EEG recordings for clinician review.
Why it matters Automatic event detection is the layer where EEG reading is actually being automated, and each clearance in the category fixes the regulatory baseline that later detection algorithms will be measured against.

Nihon Kohden's EEG-1260A Neurofax System Clears FDA 510(k)

Nihon Kohden's EEG-1260A Neurofax system, along with its amplifier unit and photic stimulator, received FDA 510(k) clearance on October 9, 2025. The device is a Class II medical device in the neurology specialty, with software for quantitative EEG analysis. The traditional 510(k) clearance indicates substantial equivalence to a legally marketed device.
Why it matters Clinical EEG's incumbent vendors keep clearing quantitative-analysis software through the 510(k) route, setting the predicate ladder that newer neural-interface entrants will have to climb to reach the same hospital installed base.
September 2025

Neuropixels Ultra Doubles Neuron Yield With 6-Micrometer Site Spacing

A Neuron paper describes Neuropixels Ultra, which packs 6,144 switchable recording sites at 6-micrometer center-to-center spacing while reading 384 channels simultaneously. In mouse visual cortex recordings, neuronal yield increased by more than twofold. The study also improved subcellular signal detection and cell-type classification, but it did not report simultaneous recording from 10,000 neurons.
Why it matters The paper separates site density from neuron count and shows where the denser probe actually helps, preventing a 6,144-site design from being misreported as 10,000 simultaneous neurons.

Chinese Hospital Opens Its Own Brain-Computer Interface Research Institute

Tongji Hospital in Wuhan announced a brain-computer interface research institute on 5 September 2025, which it says is the first of its kind run by a hospital in China rather than by a university or a company. The institute covers basic research, clinical application and commercialisation, with the stated aim of building a full-chain BCI system spanning prevention, diagnosis, treatment and rehabilitation of neurological disease.
Why it matters Clinical translation of BCI in China has largely been driven by university labs and companies, with hospitals serving as trial sites and sources of patients. A hospital standing up its own institute is a claim to a position further up that chain, closing the loop of assessment, enrolment, surgical technique, follow-up and device iteration inside the hospital itself. What followed bears that out: the same hospital performed China's first BCI procedure billed under a published medical service price about two months later, and in March 2026 led the formation of a provincial BCI innovation centre, with the institute's director heading that centre too.

FDA Clears Forest Devices SignalNED EEG System

The FDA cleared Forest Devices' SignalNED System (Model RE) on September 3, 2025, finding it substantially equivalent under submission number K251726 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Forest Devices has applied reduced-montage EEG to prehospital stroke identification, acquiring interpretable signals in settings such as ambulances.
Why it matters Prehospital stroke triage is the rare EEG use case with a hard time constraint and a clear decision attached to the reading, which makes it the strongest commercial argument for reduced-montage hardware outside the hospital.
May 2025

Neuracle Completes Trial of Its Wireless NEO Implant in Tetraplegia

Neuracle Medical Technology (Shanghai) Co., Ltd. ran a clinical trial in China evaluating the safety and efficacy of its implantable wireless brain-computer interface, NEO, in patients with tetraplegia caused by spinal cord injury. The trial is registered on ClinicalTrials.gov as NCT06990412 and is listed as completed; its stated primary purpose was to provide the basis for product registration. NEO is designed to let patients control external devices with brain signals.
Why it matters A registration-purpose trial reaching completion is a different milestone from a first-in-human implant: it is the point at which a Chinese invasive BCI has a data package to take to regulators, which sets the pace the rest of the domestic field will be measured against.

Shandong Issues BCI Industry Innovation Plan

Thirteen departments in China's Shandong province, led by the Department of Science and Technology, jointly issued the Action Plan for Scientific and Technological Innovation in the Brain-Computer Interface Industry in Shandong (2025-2027), document number Lu Ke Zi [2025] No. 50, dated May 13, 2025 and released on May 16. By 2027 the province aims for roughly 20 breakthroughs in frontier and core technologies, about 30 innovative technology SMEs, two to three high-level talent teams, and one to two specialised incubators in areas rich in research and education resources, with applications reaching medicine, industry, elderly care, education and entertainment. By 2030 it expects an initial BCI industry ecosystem. The plan organises work into six campaigns and backs Jinan and Qingdao as innovation clusters. It is the first of Shandong's two provincial BCI documents and covers the industrial side.
Why it matters Shandong is the only province to split its BCI policy across two documents with different lead agencies. This industry-side plan came first under the science and technology department, and its 2027 targets were later carried over verbatim into the health commission's clinical translation plan, so the two must be read together.

© 2026 BCIwiki.com Digest Topics Tips Subscribe Revisions About